Status:

RECRUITING

The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis

Lead Sponsor:

David Grant U.S. Air Force Medical Center

Conditions:

Knee Osteoarthritis (OA)

Eligibility:

All Genders

45-75 years

Phase:

PHASE2

Brief Summary

Our purpose is to expand upon the results of the pilot study performed at David Grant Medical Center (DGMC) which showed that concomitant non-steroidal NSAID use in adults with knee osteoarthritis (OA...

Eligibility Criteria

Inclusion

  • Must be DoD Healthcare beneficiaries empaneled at DGMC
  • Adults aged 45-75 years with a clinical diagnosis of Knee OA (either unilateral or bilateral) based on clinical and radiographic criteria as defined by the American College of Rheumatology (Altman 1987)
  • Knee radiographs (within 2 years of start date) with Kellgren-Lawrence classification of 2-3
  • Moderate to severe Knee pain for at least 3 months defined as a score of ≥4 using the NPRS (0-10) in response to the question "What is the average level of your left/ right knee pain in the past 3 months?"
  • English speaking
  • Not pregnant
  • Not breastfeeding
  • No allergy to dextrose, lidocaine, or sulfite

Exclusion

  • Previous knee replacement surgery
  • Previous meniscus repair/debridement surgery or chondral replacement surgery
  • Any intra-articular injection including steroid, prolotherapy or platelet rich plasms within the previous 3 months
  • Significant effusion as defined by a ballotable patella
  • Pregnancy or breastfeeding
  • Current/ongoing medical problems obtained from chart review contraindicating NSAID use to include chronic kidney disease stage II or higher, acute interstitial nephritis, coronary artery disease requiring percutaneous coronary intervention (PCI) or bypass surgery; Major Adverse Coronary Event (MACE), body mass index (BMI) ≥40, inflammatory arthropathy (gouty arthritis, psoriatic arthritis, or septic arthritis), history of GI bleed.
  • Non-English speaking
  • Allergy to dextrose, lidocaine, or sulfite

Key Trial Info

Start Date :

March 31 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2026

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT06911359

Start Date

March 31 2025

End Date

December 31 2026

Last Update

November 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

David Grant USAF Medical Center

Travis AFB, California, United States, 94535